Celltrion USA Announces Two-Year Data For ZYMFENTRATM(Infliximab-Dyyb) To Be Presented At Digestive Disease Week (DDW) ...
(MENAFN- PR Newswire) Data presentations including the extended LIBERTY studies to highlight the long-term treatment goals of ZYMFENTRATM, the first and only FDA-approved subcutaneous infliximab The data underscores Celltrion's commitment to improving …